Clovis Oncology Stock Price

-0.07 (-3.3%)
Upgrade to Real-Time
Regular Market
Volume 790,025
Bid Price 2.05
Ask Price 2.06
News -
Day High 2.08


52 Week Range


Day Low 2.01
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Clovis Oncology Inc CLVS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.07 -3.3% 2.05 10:29:46
Open Price Low Price High Price Close Price Prev Close
2.04 2.01 2.08 2.12
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,656 790,025 $ 2.04 $ 1,609,171 - 1.9701 - 11.10
Last Trade Time Type Quantity Stock Price Currency
10:29:46 100 $ 2.05 USD


Draw Mode:

Clovis Oncology Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 266.46M 129.98M 127.34M $ 164.52M $ - -4.44 -0.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -20.00k 1.50%

more financials information »

Clovis Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CLVS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.642.661.97012.295,784,257-0.59-22.35%
1 Month2.87783.141.97012.584,439,307-0.8278-28.77%
3 Months4.56494.761.97013.084,131,076-2.51-55.09%
6 Months4.885.241.97013.763,378,247-2.83-57.99%
1 Year6.8011.101.97016.116,496,804-4.75-69.85%
3 Years24.1332.051.97017.555,629,910-22.08-91.5%
5 Years59.8899.451.970114.664,058,769-57.83-96.58%

Clovis Oncology Description

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.

Your Recent History
Clovis Onc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.